1131114BLS
-
00:00
1.
Positive Affect: Unmet Need of Depression Treatment?
-
00:24
2.
《與神同行》 신과함께: 죄와벌
-
00:25
3.
Positive Affect: Unmet Need of Depression Treatment?
-
04:47
4.
《與神同行》 신과함께: 죄와벌
-
05:35
5.
Slide 3
-
05:56
6.
World Health Organization
-
06:40
7.
Slide 5
-
07:15
8.
6
-
07:51
9.
Distribution of depression cost is characterized by high indirect costs
-
08:14
10.
Impact of depression on life expectancy :Depression kills
-
08:30
11.
Non-Suicidal MortalityMortality during 22.6 year follow-up (1.095.338 Swedish young men – 18.3 year old)
-
08:45
12.
Slide 12
-
09:18
13.
Slide 13
-
09:35
14.
憂鬱症治療的 三重難題(地獄)
-
10:21
15.
How effective are contemporary antidepressants?
-
10:41
16.
How about REMISSION?
-
11:06
17.
Treatment Resistant Depression
-
11:53
18.
Slide 21
-
12:22
19.
Maudsley Staging Model for TRD
-
12:29
20.
Repeated inadequate drug trials
-
12:59
21.
Initial Inadequate Response
-
13:05
22.
DSM : the problem of heterogeneity
-
13:49
23.
DSM versus assessment tools :Diversity in depressive symptoms
-
15:11
24.
Center for Epidemiological Studies-Depression (CES-D)
-
15:38
25.
Lack of positive mood is most specific for depression
-
15:52
26.
Dimensions of Major Depressive Disorder
-
16:16
27.
Towards a more dimensional approach to MDD ?
-
17:57
28.
Factors identified by depressed outpatients as very important in defining remission
-
19:05
29.
Is what we measure what matters for patients?
-
21:18
30.
Divergence in expectations between physician and patient influences 6 month outcome ( Multivariate - with baseline continuous divergence index )
-
21:43
31.
Symptomatic Remission or Functional Remission
-
23:06
32.
Symptoms and functioning
-
23:46
33.
Clinical factors associated with an improvement of social functioning: the ACTIF study
-
24:23
34.
Slide 44
-
25:39
35.
Residual symptoms may be the norm
-
27:33
36.
Correlation Between Hippocampal Volume and Duration of Untreated Depression
-
28:24
37.
Distribution of SDS occupational impairment scores in fully remitted patients
-
28:48
38.
沒有回復『生氣勃勃』的remission
-
29:11
39.
Dopamine/Serotonin competition/cooperation
-
30:48
40.
Slide 52
-
31:06
41.
For instance
-
31:41
42.
Slide 54
-
33:57
43.
Symptom change in CBT
-
34:31
44.
Slide 56
-
35:32
45.
Conclusions
-
36:30
46.
REMAINING CHALLENGE: Remission vs. Recovery
-
37:18
47.
我們還有很長的路要走
-
37:42
48.
我們還有很長的路要走
-
38:03
49.
Slide 94
-
38:30
50.
Is what we measure what matters for patients?
-
00:00
1.
Positive Affect: Unmet Need of Depression Treatment?
-
00:24
2.
《與神同行》 신과함께: 죄와벌
-
00:25
3.
Positive Affect: Unmet Need of Depression Treatment?
-
04:47
4.
《與神同行》 신과함께: 죄와벌
-
05:35
5.
Slide 3
-
05:56
6.
World Health Organization
-
06:40
7.
Slide 5
-
07:15
8.
6
-
07:51
9.
Distribution of depression cost is characterized by high indirect costs
-
08:14
10.
Impact of depression on life expectancy :Depression kills
-
08:30
11.
Non-Suicidal MortalityMortality during 22.6 year follow-up (1.095.338 Swedish young men – 18.3 year old)
-
08:45
12.
Slide 12
-
09:18
13.
Slide 13
-
09:35
14.
憂鬱症治療的 三重難題(地獄)
-
10:21
15.
How effective are contemporary antidepressants?
-
10:41
16.
How about REMISSION?
-
11:06
17.
Treatment Resistant Depression
-
11:53
18.
Slide 21
-
12:22
19.
Maudsley Staging Model for TRD
-
12:29
20.
Repeated inadequate drug trials
-
12:59
21.
Initial Inadequate Response
-
13:05
22.
DSM : the problem of heterogeneity
-
13:49
23.
DSM versus assessment tools :Diversity in depressive symptoms
-
15:11
24.
Center for Epidemiological Studies-Depression (CES-D)
-
15:38
25.
Lack of positive mood is most specific for depression
-
15:52
26.
Dimensions of Major Depressive Disorder
-
16:16
27.
Towards a more dimensional approach to MDD ?
-
17:57
28.
Factors identified by depressed outpatients as very important in defining remission
-
19:05
29.
Is what we measure what matters for patients?
-
21:18
30.
Divergence in expectations between physician and patient influences 6 month outcome ( Multivariate - with baseline continuous divergence index )
-
21:43
31.
Symptomatic Remission or Functional Remission
-
23:06
32.
Symptoms and functioning
-
23:46
33.
Clinical factors associated with an improvement of social functioning: the ACTIF study
-
24:23
34.
Slide 44
-
25:39
35.
Residual symptoms may be the norm
-
27:33
36.
Correlation Between Hippocampal Volume and Duration of Untreated Depression
-
28:24
37.
Distribution of SDS occupational impairment scores in fully remitted patients
-
28:48
38.
沒有回復『生氣勃勃』的remission
-
29:11
39.
Dopamine/Serotonin competition/cooperation
-
30:48
40.
Slide 52
-
31:06
41.
For instance
-
31:41
42.
Slide 54
-
33:57
43.
Symptom change in CBT
-
34:31
44.
Slide 56
-
35:32
45.
Conclusions
-
36:30
46.
REMAINING CHALLENGE: Remission vs. Recovery
-
37:18
47.
我們還有很長的路要走
-
37:42
48.
我們還有很長的路要走
-
38:03
49.
Slide 94
-
38:30
50.
Is what we measure what matters for patients?
- 位置
-
- 資料夾名稱
- 保健中心
- 發表人
- 江堤莊
- 單位
- 台大醫學院資訊組
- 建立
- 2019-11-17 17:19:38
- 最近修訂
- 2019-11-17 18:21:33
- 長度
- 39:44